CDK12 and cancer: Immunotherapy-based approaches have enriched the therapeutical opportunities of many cancer types, improving patient survival; however, to date, in advanced PCa patients, it has no established role outside of retrospective small series data on dMMR/MSI high and CDK12 patients [60].